The U.S. Food & Drug Administration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…
Recent research has found a higher does of anifrolumab may benefit patients with moderate to severe SLE…
Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…
(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website. The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. The label for the…
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…
More than half of regular opioid users suffer from arthritis. Here are three tips to talk to your patients about opioid use and alternative pain management…
WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill. “We will soon be putting more options on…
Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…
The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…